Journal profile · Oncology
Asia-Pacific Journal of Clinical Oncology
ISSN 1743-7555 · eISSN 1743-7563 · Wiley · AUSTRALIA · Bi-monthly · Founded 2005
Asia-Pacific Journal of Clinical Oncology: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 1.48; hybrid open access; APC about USD 3,700; median 147 days to acceptance (71 articles, last 24 months); community-reported acceptance: easy; 152 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Asia-Pacific Journal of Clinical Oncology is published by Wiley and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Diverse Scientific and Economic Studies, Human auditory perception and evaluation and Multiple and Secondary Primary Cancers, together about 18.7% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
Asia–Pacific Journal of Clinical Oncology is a multidisciplinary journal of oncology that aims to be a forum for facilitating collaboration and exchanging information on what is happening in different countries of the Asia–Pacific region in relation to cancer treatment and care. The Journal is ideally positioned to receive publications that deal with diversity in cancer behavior, management and outcome related to ethnic, cultural, economic and other differences between populations. In addition to original articles, the Journal publishes reviews, editorials, letters to the Editor and short communications. Case reports are generally not considered for publication, only exceptional papers in which Editors find extraordinary oncological value may be considered for review. The Journal encourages clinical studies, particularly prospectively designed clinical trials.
From the journal's Aims & Scope
Research area (LetPub): Oncology
Editor-in-chief Stephen AcklandPublisher website
Editorial board by country: 8 in mainland China (about 22%); most named Mainland China 8, Japan 6, Australia 6, South Korea 5, Singapore 4 (37 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Diverse Scientific and Economic StudiesEconomics, Econometrics and Finance6.5%
- Human auditory perception and evaluationEngineering6.3%
- Multiple and Secondary Primary CancersMedicine5.9%
- Economic and Financial Impacts of CancerEconomics, Econometrics and Finance5.9%
- Lung Cancer Treatments and MutationsMedicine5.2%
- Advances in Oncology and RadiotherapyMedicine5.1%
- Cancer Immunotherapy and BiomarkersMedicine4.8%
- Cancer survivorship and careMedicine4.5%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEPubMedEmbasePublisher website
Other: EBSCO
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 1.48LetPub ·
- Impact factor (publisher) 2025
- 2.1Publisher website ·
- CiteScore 2026-06
- 3.9LetPub ·
- CiteScore (publisher) 2025
- 3.9Publisher website ·
- SJR 2026-06
- 0.56LetPub ·
- SNIP 2026-06
- 0.62LetPub ·
- h-index
- 23LetPub ·
- h-index
- 56OpenAlex ·
- i10-index
- 671OpenAlex ·
- 2-year mean citedness
- 1.02OpenAlex ·
- Self-citation rate
- 4.8%LetPub ·
- Share of gold OA articles
- 36.4%LetPub ·
Volume
- Articles per year
- 102LetPub ·
- Articles per year (publisher) 2025
- 114Publisher website ·
- Downloads per year (publisher) 2025
- 296,250Publisher website ·
Articles by year OpenAlex count · 3,506 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 124 | 47 | 12 |
| 2025 | 152 | 88 | 134 |
| 2024 | 103 | 54 | 240 |
| 2023 | 132 | 88 | 511 |
| 2022 | 204 | 67 | 1,063 |
| 2021 | 218 | 96 | 1,120 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
147 daysMedian, submission to acceptance · P25–P75 99 days – 266 days
- Acceptance to online
- median 16 days (73 articles)
- Submission to online
- median 177 days
- Sample
- 71 articles with submission and acceptance dates (290 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- EasyLetPub ·
- Acceptance rate (publisher) 2025
- 15%Publisher website ·
- Submission to first decision 2025
- 21 daysPublisher website ·
- Submission to acceptance 2025
- 247 daysPublisher website ·
- Acceptance to publication 2025
- 13 daysPublisher website ·
- Peer review
- Single-anonymous peer review, at least 2 reviewersPublisher website · model-extracted
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 3,700 / EUR 3,070 / GBP 2,510 | — | — | |
| Publisher website | Yes, amount not published | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare6 items from the author guidelines
- Abstract
- ≤ 250 words
- Reference style
- Vancouver
- First submission
- Free format: the journal's layout is not required
- Suggested reviewers
- Optional
- Graphical abstract
- Required
- Cover letter
- Required
Article types accepted6, with length limits
- case reportContributions may take the form of Original Articles, Review Articles or Letters to the Editor. Case Reports will only be considered if they are of exceptional …main text ≤ 1,500 words
- editorialThe acceptance criteria for all papers are the quality and originality of the research and its significance to our readership. Except where otherwise stated, ma…Length not stated
- letters to the editorContributions may take the form of Original Articles, Review Articles or Letters to the Editor. Case Reports will only be considered if they are of exceptional …Length not stated
- original articleContributions may take the form of Original Articles, Review Articles or Letters to the Editor. Case Reports will only be considered if they are of exceptional …main text ≤ 3,500 words
- reviewnsive analyses of specific topics. If a review longer than 5,000 words is required to discuss the topic in depth, the author shoulmain text ≤ 5,000 words
- review articleContributions may take the form of Original Articles, Review Articles or Letters to the Editor. Case Reports will only be considered if they are of exceptional …main text ≤ 5,000 words
Policy excerpts from the journal's websiteAuthorship, Conflicts of interest, Data availability, Publication ethics, Trial registration / reporting guidelines
- Authorship Authorship and Acknowledgements
The journal adheres to the definition of authorship set up by The International Committee of Medical Journal Editors (ICMJE). The ICMJE recommends that authorship be based on the following 4 criteria: i) Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; ii) Drafting the work or revising it critically for importa…
Source ↗Publisher website ·- Conflicts of interest Conflicts of Interest (CoI)
Authors will be asked to provide a conflict of interest statement during the submission process. Each article must include a statement regarding CoI, regardless of whether or not a CoI exists. See ‘Conflict of Interest’ section in Editorial Policies and Ethical Considerations for details on what to include in this section. Authors should ensure they liaise with all co-authors to confirm agreement …
Source ↗Publisher website ·- Data availability Data Sharing and Data Accessibility
The journal encourages authors to share the data and other artefacts supporting the results in the paper by archiving it in an appropriate public repository. Authors should include a data accessibility statement, including a link to the repository they have used, in order that this statement can be published alongside their paper. Review Wiley’s Data Sharing policy where you will be able to see an…
Source ↗Publisher website ·- Publication ethics Publication Ethics
This journal is a member of the Committee on Publication Ethics (COPE). Note this journal uses iThenticate’s CrossCheck software to detect instances of overlapping and similar text in submitted manuscripts. Read our Top 10 Publishing Ethics Tips for Authors here. Wiley’s Publication Ethics Guidelines can be found at https://authorservices.wiley.com/ethics-guidelines/index.htmlArtificial Intelligen…
Source ↗Publisher website ·- Trial registration / reporting guidelines Prospective Clinical Trial Registration
The journal requires that the clinical trials submitted for its consideration are registered in a publicly accessible database. Authors should include the name of the trial register and their clinical trial registration number in the ‘Acknowledgements’ section of their manuscript. If you wish the editor[s] to consider an unregistered trial, please explain briefly why the trial has not been registe…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Wiley
- Country or region
- AUSTRALIA
- Language
- English
- Frequency
- Bi-monthly
- Founded
- 2005
- ISSN
- 1743-7555
- Electronic ISSN
- 1743-7563
- Official links
- Journal homepage ↗LetPub
- Submission system ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Asia-Pacific Journal of Clinical Oncology
What CAS zone is Asia-Pacific Journal of Clinical Oncology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Asia-Pacific Journal of Clinical Oncology is in Zone 4 of Medicine, and in Zone 4 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Asia-Pacific Journal of Clinical Oncology?
The latest impact factor listed by LetPub is 1.48; CiteScore 3.9, h-index 56.
How long does peer review take at Asia-Pacific Journal of Clinical Oncology?
Based on the dates recorded on 71 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 147 days (interquartile range 99–266 days); authors report an average review time of 6–12 weeks; the community-reported acceptance is “Easy”; the journal's website gives an acceptance rate of 15% (2025). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Asia-Pacific Journal of Clinical Oncology?
According to the journal's author guidelines: Abstract: ≤ 250 words; Reference style: Vancouver; First submission: Free format: the journal's layout is not required; Suggested reviewers: Optional; Graphical abstract: Required; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Asia-Pacific Journal of Clinical Oncology based?
Of the 37 board members whose country the journal's board page names, 8 (about 22%) are in mainland China; the countries named most often are Mainland China (8), Japan (6) and Australia (6). Counted from the institutions listed on the board page; for reference only.
Which databases index Asia-Pacific Journal of Clinical Oncology?
According to LetPub and DOAJ records, Asia-Pacific Journal of Clinical Oncology is indexed in SCIE and Scopus. The journal's website also lists MEDLINE, PubMed and Embase; that list has not been checked against each database.
Is Asia-Pacific Journal of Clinical Oncology open access, and what is the APC?
Asia-Pacific Journal of Clinical Oncology is a hybrid journal. For open-access publication: APC about USD 3,700.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .